Viatris Inc (Viatris) is a pharmaceutical company. It offers a diverse portfolio of products and services, including branded drugs, generics, and complex generics in the form of oral solid doses, injectables, complex dosage forms, and APIs. The company produces medicines in therapeutic areas such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's healthcare. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. Viatris also focuses on increasing access to treatments for HIV/AIDS, hepatitis, and tuberculosis.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Viatris is focused on the expansion of its innovative portfolio through the development of complex and novel products to address unmet medical needs. The company leverages its broad and diverse portfolio, in-house development capabilities, and strategic alliances to pursue generics opportunities, enhance existing products, and expand access through new product submissions. Viatris invests significantly in research and development (R&D) to drive growth and build a higher margin portfolio with exclusivity opportunities. The R&D units include technology-focused development sites and global R&D centers. These units are responsible for collaborating across the company's different R&D centers worldwide to deliver new product opportunities, evaluate opportunities to expand the existing product portfolio, and focus on development activities. In FY2025, the company spent US$965.9 million on its R&D activities, which as a percentage of revenue, stood at 6.8% and grew 19.4% YoY. As of December 2025, the company filed more than 1,400 patents and had more than 27,000 trademarks filed globally. A few of the company's pipeline products in phase III include Effexor to treat generalized anxiety disorder (GAD); Xulane low dose to treat contraception; Meloxicam fast acting oral formulation to treat acute pain; Nefecon to treat IgA Nephropathy; Norelgestromin to treat contraception; Pimecrolimus Ophthalmic Ointment (MR-139) to treat blepharitis; Phentolamine Ophthalmic Solution (MR-141) to treat Presbyopia; Phentolamine Ophthalmic Solution (MR-142) to treat visual loss in low light conditions associated with keratorefractive surgery; Selatogrel to treat acute myocardial infarction (AMI); Cenerimod to treat systemic lupus erythematosus (SLE); and Sotagliflozin to treat heart failure.